Your session is about to expire
← Back to Search
Alkylating Agent
Chemotherapy + Ponatinib for Acute Lymphoblastic Leukemia
Phase 2
Waitlist Available
Led By Elias Jabbour
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of previously untreated Ph-positive ALL (either t[9;22] and/or bcr-abl positive) or with lymphoid accelerated or blast phase chronic myelogenous leukemia (CML)
Performance status =< 2 (Eastern Cooperative Oncology Group [ECOG] scale)
Must not have
Active grade III-V cardiac failure as defined by the New York Heart Association criteria
Active serious infection not controlled by oral or intravenous antibiotics
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
Summary
This trial is testing a combination of drugs to treat leukemia and measure any side effects.
Who is the study for?
This trial is for patients with untreated or previously treated Ph-positive acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia (CML) in blast phase. Participants must be physically able to perform daily activities with minimal assistance, have normal organ function, and agree to use effective contraception. Excluded are those with serious infections, active hepatitis B, severe heart conditions, uncontrolled blood pressure, a history of significant bleeding disorders unrelated to cancer, or alcohol abuse.Check my eligibility
What is being tested?
The study tests how well a combination of chemotherapy drugs like cyclophosphamide and doxorubicin hydrochloride works alongside ponatinib hydrochloride—a drug that blocks enzymes needed for cancer cell growth—in treating ALL. It's a phase II trial aiming to determine the effectiveness and side effects of this treatment regimen.See study design
What are the potential side effects?
Possible side effects include damage to organs from chemotherapy drugs such as nausea and hair loss; ponatinib may cause issues like high blood pressure or pancreatitis. The severity can vary widely among individuals.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with a specific type of leukemia for the first time.
Select...
I can do most of my daily activities on my own.
Select...
I am a woman who can have children and have a negative pregnancy test.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have severe heart failure.
Select...
I have a serious infection that isn't getting better with antibiotics.
Select...
I do not have serious heart or blood vessel problems.
Select...
I have been treated with ponatinib for more than a month.
Select...
I have had pancreatitis within the last year or suffer from chronic pancreatitis.
Select...
I have a history of a serious bleeding disorder not related to my cancer.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Event-free survival
Secondary outcome measures
Complete response rate
Disease-specific survival
Incidence of grade 3-4 toxicity according to the M.D. Anderson Leukemia-specific Adverse Event Recording and Reporting Guidelines
+1 moreSide effects data
From 2023 Phase 2 trial • 27 Patients • NCT0400240188%
Pyrexia
65%
Neutrophil count decreased
62%
Nausea
58%
Hypotension
50%
Anaemia
46%
Headache
38%
Decreased appetite
38%
Fatigue
35%
Confusional state
31%
Diarrhoea
31%
Hypokalaemia
31%
Tachycardia
27%
Constipation
27%
Back pain
27%
Hypophosphataemia
23%
Platelet count decreased
23%
Dizziness
23%
Tremor
23%
B-cell lymphoma
23%
White blood cell count decreased
19%
Hyponatraemia
19%
Hypogammaglobulinaemia
19%
Tachypnoea
19%
Oedema peripheral
19%
Neutropenia
19%
Cough
19%
Agitation
15%
Chills
15%
Hypomagnesaemia
15%
Alanine aminotransferase increased
15%
Thrombocytopenia
15%
Dyspnoea
15%
Sinus tachycardia
15%
Dysphagia
12%
Covid-19
12%
Aspartate aminotransferase increased
12%
Hyperglycaemia
12%
Abdominal pain
12%
Hypoxia
12%
Vomiting
12%
Malaise
12%
Hypertension
12%
Pain
12%
Myalgia
12%
Arthralgia
12%
Peripheral sensory neuropathy
8%
Gait disturbance
8%
Blood creatinine increased
8%
Lymphocyte count decreased
8%
Dysuria
8%
Pancytopenia
8%
Sepsis
8%
Hyperhidrosis
8%
Oral candidiasis
8%
Urinary tract infection
8%
Aphasia
8%
Muscular weakness
8%
Pneumonia
8%
Encephalopathy
8%
Eye pain
8%
Acute myeloid leukaemia
8%
Insomnia
8%
Somnolence
8%
Asthenia
4%
Embolism
4%
Respiratory failure
4%
Pleural effusion
4%
Covid-19 pneumonia
4%
Febrile neutropenia
4%
Depression
4%
Syncope
100%
80%
60%
40%
20%
0%
Study treatment Arm
Axicabtagene Ciloleucel and Rituximab Combination
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (combination chemotherapy, ponatinib hydrochloride)Experimental Treatment13 Interventions
See Detailed Description.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
1999
Completed Phase 4
~2200
Vincristine Sulfate
2005
Completed Phase 3
~10160
Ponatinib Hydrochloride
2014
Completed Phase 2
~20
Dexamethasone
2007
Completed Phase 4
~2640
Doxorubicin Hydrochloride
2019
Completed Phase 3
~17860
Methotrexate
2013
Completed Phase 4
~3800
Ponatinib
2015
Completed Phase 2
~820
Prednisone
2014
Completed Phase 4
~2370
Vincristine
2003
Completed Phase 4
~2910
Doxorubicin
2012
Completed Phase 3
~7940
Cytarabine
2016
Completed Phase 3
~3310
Cyclophosphamide
1995
Completed Phase 3
~3770
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,002 Previous Clinical Trials
1,794,191 Total Patients Enrolled
Elias JabbourPrincipal InvestigatorM.D. Anderson Cancer Center
16 Previous Clinical Trials
948 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have active hepatitis B but am on treatment to control it.I have another cancer besides skin cancer that may shorten my life to under a year.I do not have severe heart failure.I have a serious infection that isn't getting better with antibiotics.I do not have serious heart or blood vessel problems.I have been treated with ponatinib for more than a month.My fluid buildup in the chest or heart area is due to my leukemia.I have been diagnosed with a specific type of leukemia for the first time.I have ALL or CML and have had 1-2 chemotherapy treatments.I can do most of my daily activities on my own.I am a woman who can have children and have a negative pregnancy test.I haven't taken any experimental cancer drugs or chemotherapy in the last week.My heart is healthy based on recent exams.I have had pancreatitis within the last year or suffer from chronic pancreatitis.I have a history of a serious bleeding disorder not related to my cancer.I agree to use effective birth control during and for 4 months after treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment (combination chemotherapy, ponatinib hydrochloride)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger